The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2019 | Predicting resistance in CLL patients
Danielle Brander, MD, Duke University School of Medicine, Durham, NC, describes the process by which we aim to predict which patients will develop resistance to chronic lymphocytic leukemia (CLL) treatment, with particular reference to venetoclax treatment. This interview was recorded at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.
